Can prasugrel be discontinued two years after stent placement?

Can Prasugrel Be Stopped 2 Years After Stent Placement?

Yes, prasugrel can generally be discontinued 2 years after stent placement, as the standard recommended duration of dual antiplatelet therapy (DAPT) is 12 months for patients with acute coronary syndrome (ACS) treated with PCI, though continuation beyond 12 months may be reasonable in select patients without bleeding complications.

Standard Duration Recommendations

The 2016 ACC/AHA guidelines establish that P2Y12 inhibitor therapy (including prasugrel) should be given for at least 12 months after stent placement in ACS patients 1. This represents the Class I, Level B-R recommendation that forms the foundation of post-PCI antiplatelet management. The 2017 ESC guidelines similarly recommend a default 12-month DAPT duration for ACS patients regardless of revascularization strategy 2.

Extended Duration Considerations

After completing the mandatory 12-month period, continuation beyond 12 months receives a Class IIb recommendation (may be reasonable) in patients who:

• Have tolerated DAPT without bleeding complications
• Are not at high bleeding risk
• Have no history of prior bleeding on DAPT, coagulopathy, or oral anticoagulant use 1

The DAPT trial demonstrated that extending prasugrel therapy to 30 months (compared to 12 months) reduced stent thrombosis (0.4% vs 1.4%) and major adverse cardiovascular events (4.3% vs 5.9%), but increased moderate-to-severe bleeding (2.5% vs 1.6%) and showed a trend toward increased all-cause mortality 3. A subset analysis specific to prasugrel patients with paclitaxel-eluting stents showed even more pronounced benefits with 30-month therapy 4.

Decision Algorithm at 2 Years

At 2 years post-stent, you should discontinue prasugrel unless:

1. High ischemic risk features present:

   • Prior stent thrombosis without correctable cause
   • Complex PCI (≥3 stents, ≥3 lesions, bifurcation, total length ≥60mm, left main)
   • Peripheral arterial disease
   • Diabetes with prior MI
   • Recurrent ACS events

2. Patient has tolerated therapy without bleeding

3. No high bleeding risk factors:

   • Age ≥75 years (prasugrel generally not recommended) 5
   • Body weight <60 kg
   • History of stroke/TIA (absolute contraindication for prasugrel) 5
   • Concurrent oral anticoagulation
   • Prior significant bleeding on DAPT

Critical Safety Considerations

The FDA label warns that premature discontinuation increases risk of stent thrombosis, MI, and death 5. However, this warning primarily applies to early discontinuation (within the first 12 months). Research shows MI rates increase within 90 days of prasugrel cessation after both 12 and 30 months of treatment 4, suggesting a rebound phenomenon regardless of duration.

Important caveats:

• Real-world data from the RENAMI registry showed that DAPT >12 months with prasugrel/ticagrelor reduced net adverse clinical events in unselected ACS patients, but this benefit was not observed in patients >75 years or females due to excess bleeding 6
• The bleeding risk with prasugrel is substantial and includes fatal bleeding, particularly in elderly patients 5

Practical Recommendation

For a typical ACS patient 2 years post-stent on prasugrel: discontinue the prasugrel and continue aspirin 81mg daily indefinitely 1. The mandatory 12-month period is complete, and extending to 24 months already exceeds the evidence-based recommendations for most patients. Only continue beyond 2 years if the patient has very high ischemic risk features (prior stent thrombosis, complex disease, diabetes with prior MI) AND has had zero bleeding complications.

Monitor closely for 90 days after discontinuation, as this is when rebound ischemic events may occur 4.